Don't mind the brand name Haloette in fact I think it is quite brilliant. Even though approval has been delayed the fact that it now can be detailed along side Nextellis will generate complimentary prescriber awareness. The benefit of a better shelf life is a positive and the need for longer term stability studies explains the delay in gaining approval. I also cannot believe that it has not been tagged as market sensitive. It is a valuable addition to the strategic portfolio of women's health specialty products.
Ann: FDA approval of HALOETTE, a generic version of NUVARING, page-18
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$4.87 |
Change
-0.160(3.18%) |
Mkt cap ! $396.4M | |||
| Open | High | Low | Value | Volume |
| $5.03 | $5.03 | $4.87 | $774.7K | 157.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 3782 | $4.87 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.89 | 727 | 6 |
View Market Depth
| Last trade - 12.56pm 23/06/2025 (20 minute delay) ? |
| MYX (ASX) Chart |